Experimental diabetes induced by alloxan and streptozotocin: The current state of the art

Radenković, Miroslav; Stojanović, Marko; Prostran, Milica

doi:10.1016/j.vascn.2015.11.004

Cited by 212 publications

(142 citation statements)

References 181 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…They were then intraperitoneally induced with alloxan monohydrate (alloxan monohydrate A7413, Sigma Aldrich., St.Louise, MO, USA) at a dose of 150 mg/kg to stimulate a diabetic condition. 20 Preparation of alloxan was subsequently performed by dissolving 0.9 grams of alloxan monohydrate into 6ml of PBS to produce a concentrate of 150 mg/ml. 21 The rats did not receive food or water for more than 12 hours overnight before the induction of alloxan occurred.…”

Section: Methodsmentioning

confidence: 99%

Increase of collagen in diabetes-related traumatic ulcers after the application of liquid smoke coconut shell

Surboyo

Arundina

Rahayu

2017

Dent. J. (Maj. Ked. Gigi)

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Increase of collagen in diabetes-related traumatic ulcers after the application of liquid smoke coconut shell

Surboyo

Arundina

Rahayu

2017

Dent. J. (Maj. Ked. Gigi)

View full text Add to dashboard Cite

“…Relative beta cell depletion and loss of beta cell function are also thought to be important factors in the development of T2D, although in the case of T2D, the process is not thought to be autoimmune in nature [19]. One method of inducing diabetes using a wild-type animal is by administering streptozotocin (STZ), a pharmacological agent that induces beta cell destruction by intracellular alkylation of DNA and subsequent beta cell necrosis [20–22]. There is variability in the timing, dosage and frequency of STZ injections and different protocols can be employed to mimic T1D or T2D in a variety of species/strains [20,23–25].…”

Section: Introductionmentioning

confidence: 99%

“…One method of inducing diabetes using a wild-type animal is by administering streptozotocin (STZ), a pharmacological agent that induces beta cell destruction by intracellular alkylation of DNA and subsequent beta cell necrosis [20–22]. There is variability in the timing, dosage and frequency of STZ injections and different protocols can be employed to mimic T1D or T2D in a variety of species/strains [20,23–25]. The mouse model utilising five doses of STZ at low dose (50–60 mg/kg/day) has been extensively used to mimic T1D due to the progression destruction of beta cell mass [20].…”

Section: Introductionmentioning

confidence: 99%

Mouse Models of Diabetes, Obesity and Related Kidney Disease

et al. 2016

View full text Add to dashboard Cite

Multiple rodent models have been used to study diabetic kidney disease (DKD). The purpose of the present study was to compare models of diabetes and obesity-induced metabolic syndrome and determine differences in renal outcomes. C57BL/6 male mice were fed either normal chow or high fat diet (HFD). At postnatal week 8, chow-fed mice were randomly assigned to low-dose streptozotocin (STZ, 55 mg/kg/day, five consecutive days) or vehicle control, whereas HFD-fed mice were given either one high-dose of STZ (100 mg/kg) or vehicle control. Intraperitoneal glucose tolerance tests were performed at Week 14, 20 and 30. Urinary albumin to creatinine ratio (ACR) and serum creatinine were measured, and renal structure was assessed using Periodic Acid Schiff (PAS) staining at Week 32. Results showed that chow-fed mice exposed to five doses of STZ resembled type 1 diabetes mellitus with a lean phenotype, hyperglycaemia, microalbuminuria and increased serum creatinine levels. Their kidneys demonstrated moderate tubular injury with evidence of tubular dilatation and glycogenated nuclear inclusion bodies. HFD-fed mice resembled metabolic syndrome as they were obese with dyslipidaemia, insulin resistance, and significantly impaired glucose tolerance. One dose STZ, in addition to HFD, did not worsen metabolic features (including fasting glucose, non esterified fatty acid, and triglyceride levels). There were significant increases in urinary ACR and serum creatinine levels, and renal structural changes were predominantly related to interstitial vacuolation and tubular dilatation in HFD-fed mice.

show abstract

“…After an overnight (12 h) fast, SD rats were made diabetic by intravenous administration of 1% alloxan (Sigma, Shanghai, China) dissolved in 0.9% saline given as a single dose of 45 mg/kg body weight (Radenković et al, 2016). Half-an-hour later, the rats were given 20% glucose by intragastric administration at a dose of 2 ml/rat and then allowed free access to food (standard pellet diet) and water.…”

Section: Induction Of Diabetesmentioning

confidence: 99%

Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes

et al. 2016

View full text Add to dashboard Cite

Subcutaneous liraglutide-loaded multivesicular liposomes (Lrg-MVLs) were developed as a sustained drug-delivery system for treating diabetes and their properties were characterized. The Lrg-MVLs prepared using a two-step water-in-oil-in-water double emulsification process had a spherical appearance with a mean diameter of 6.69 mm and an encapsulation efficiency of 82.23 ± 4.78% without any initial burst release. Their pharmacodynamics (PD) and pharmacokinetics (PK) were also studied after a single subcutaneous administration to Sprague-Dawley (SD) rats with diabetes. The PD results demonstrated that Lrg-MVLs presented sustained glucose-lowering effects for nearly a week, while the pharmacokinetic parameters showed that the plasma liraglutide concentration of the designed preparation produced C max of 81.979 ± 12.140 pg/ml and an MRT 0-t of 88.224 ± 3.893 h. Furthermore, retention of Lrg-MVLs at the injection site was studied semiquantitatively by an in vivo imaging system, which can be used to evaluate the drug release from MVLs in vivo. In conclusion, MVLs are a promising carrier for liraglutide and Lrg-MVLs deserve further study for the treatment of diabetes.

show abstract

Experimental diabetes induced by alloxan and streptozotocin: The current state of the art

Cited by 212 publications

References 181 publications

Increase of collagen in diabetes-related traumatic ulcers after the application of liquid smoke coconut shell

Increase of collagen in diabetes-related traumatic ulcers after the application of liquid smoke coconut shell

Mouse Models of Diabetes, Obesity and Related Kidney Disease

Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes

Contact Info

Product

Resources

About